SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Santiago Quirce, Irina Bobolea, Pilar Barranco, Asma: actualización terapéutica, Medicina Clínica, 2014, 142, 7, 317

    CrossRef

  2. 2
    Jeffrey B. Bice, Evelyn Leechawengwongs, Anthony Montanaro, Biologic targeted therapy in allergic asthma, Annals of Allergy, Asthma & Immunology, 2014, 112, 2, 108

    CrossRef

  3. 3
    Noel J C Snell, Discontinued drug projects in the respiratory therapeutic area during 2012, Expert Opinion on Investigational Drugs, 2014, 23, 3, 411

    CrossRef

  4. 4
    Norbert Krug, Abhya Gupta, Philipp Badorrek, Ruediger Koenen, Meike Mueller, Anna Pivovarova, James Hilbert, Kristiane Wetzel, Jens M. Hohlfeld, Chester Wood, Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis, Journal of Allergy and Clinical Immunology, 2014, 133, 2, 414

    CrossRef

  5. 5
    Fulvio Braido, Francesca Sclifò, Matteo Ferrando, Giorgio Walter Canonica, New Therapies for Allergic Rhinitis, Current Allergy and Asthma Reports, 2014, 14, 4

    CrossRef

  6. 6
    N. C. Thomson, Novel therapies targeting eosinophilic inflammation in asthma, Clinical & Experimental Allergy, 2014, 44, 4
  7. 7
    Luzheng Xue, Maryam Salimi, Isabel Panse, Jenny M. Mjösberg, Andrew N.J. McKenzie, Hergen Spits, Paul Klenerman, Graham Ogg, Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells, Journal of Allergy and Clinical Immunology, 2014, 133, 4, 1184

    CrossRef

  8. 8
    Haixia Liu, Mingrui Zheng, Jianou Qiao, Yajie Dang, Pengyu Zhang, Xianqiao Jin, Role of prostaglandin D2/CRTH2 pathway on asthma exacerbation induced by Aspergillus fumigatus, Immunology, 2014, 142, 1
  9. 9
    Peter Norman, Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs, Expert Opinion on Investigational Drugs, 2014, 23, 1, 55

    CrossRef

  10. 10
    A. Straumann, S. Hoesli, Ch. Bussmann, M. Stuck, M. Perkins, L. P. Collins, M. Payton, R. Pettipher, M. Hunter, J. Steiner, H.-U. Simon, Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis, Allergy, 2013, 68, 3
  11. 11
    J.C. Virchow, Asthma bronchiale, Der Pneumologe, 2013, 10, S1, 16

    CrossRef

  12. 12
    Paul M O'Byrne, Nizar Naji, Asthma: management of severe disease, The Lancet Respiratory Medicine, 2013, 1, 1, e3

    CrossRef

  13. 13
    Gye Young Park, Yong Gyu Lee, Evgeny Berdyshev, Sharmilee Nyenhuis, Jian Du, Panfeng Fu, Irina A. Gorshkova, Yongchao Li, Sangwoon Chung, Manjula Karpurapu, Jing Deng, Ravi Ranjan, Lei Xiao, H. Ari Jaffe, Susan J. Corbridge, Elizabeth A. B. Kelly, Nizar N. Jarjour, Jerold Chun, Glenn D. Prestwich, Eleanna Kaffe, Ioanna Ninou, Vassilis Aidinis, Andrew J. Morris, Susan S. Smyth, Steven J. Ackerman, Viswanathan Natarajan, John W. Christman, Autotaxin Production of Lysophosphatidic Acid Mediates Allergic Asthmatic Inflammation, American Journal of Respiratory and Critical Care Medicine, 2013, 188, 8, 928

    CrossRef

  14. 14
    JA Schmidt, FM Bell, E Akam, C Marshall, IA Dainty, A Heinemann, IG Dougall, RV Bonnert, CA Sargent, Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma, British Journal of Pharmacology, 2013, 168, 7
  15. 15
    A. Mari, M. Antonietta Ciardiello, G. Passalacqua, H. Vliagoftis, A. J. Wardlaw, M Wickman, Developments in the field of allergy in 2012 through the eyes of Clinical & Experimental Allergy, Clinical & Experimental Allergy, 2013, 43, 12
  16. 16
    David A. Sandham, Nicola Arnold, Heinrich Aschauer, Kamlesh Bala, Lucy Barker, Lyndon Brown, Zarin Brown, David Budd, Brian Cox, Cerys Docx, Gerald Dubois, Nicholas Duggan, Karen England, Brian Everatt, Marcus Furegati, Edward Hall, Frank Kalthoff, Anna King, Catherine J. Leblanc, Jodie Manini, Josef Meingassner, Rachael Profit, Alfred Schmidt, Jennifer Simmons, Bindi Sohal, Rowan Stringer, Matthew Thomas, Katharine L. Turner, Christoph Walker, Simon J. Watson, John Westwick, Jennifer Willis, Gareth Williams, Caroline Wilson, Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases, Bioorganic & Medicinal Chemistry, 2013, 21, 21, 6582

    CrossRef

  17. 17
    Dhananjay Desai, Christopher Newby, Fiona A. Symon, Pranabashis Haldar, Sachil Shah, Sumit Gupta, Mona Bafadhel, Amisha Singapuri, Salman Siddiqui, Joanne Woods, Athula Herath, Ian K. Anderson, Peter Bradding, Ruth Green, Nita Kulkarni, Ian Pavord, Richard P. Marshall, Ana R. Sousa, Richard D. May, Andrew J. Wardlaw, Chris E. Brightling, Elevated Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Individuals with Severe Asthma, American Journal of Respiratory and Critical Care Medicine, 2013, 188, 6, 657

    CrossRef

  18. 18
    Ioana O. Agache, From phenotypes to endotypes to asthma treatment, Current Opinion in Allergy and Clinical Immunology, 2013, 1

    CrossRef

  19. 19
    Michael E. Wechsler, Inhibiting Interleukin-4 and Interleukin-13 in Difficult-to-Control Asthma, New England Journal of Medicine, 2013, 368, 26, 2511

    CrossRef

  20. 20
    Laura B. Fanning, Joshua A. Boyce, Lipid mediators and allergic diseases, Annals of Allergy, Asthma & Immunology, 2013, 111, 3, 155

    CrossRef

  21. 21
    Merritt L. Fajt, Sally E. Wenzel, Mast Cells, Their Subtypes, and Relation to Asthma Phenotypes, Annals of the American Thoracic Society, 2013, 10, Supplement, S158

    CrossRef

  22. 22
    Lieke W. J. van den Elsen, Yvette Nusse, Martin Balvers, Frank A. Redegeld, Edward F. Knol, Johan Garssen, Linette E. M. Willemsen, n-3 Long-chain PUFA reduce allergy-related mediator release by human mast cells in vitro via inhibition of reactive oxygen species, British Journal of Nutrition, 2013, 109, 10, 1821

    CrossRef

  23. 23
    Kian Fan Chung, New treatments for severe treatment-resistant asthma: targeting the right patient, The Lancet Respiratory Medicine, 2013, 1, 8, 639

    CrossRef

  24. 24
    Paul D. Robinson, Peter Asperen, Newer Treatments in the Management of Pediatric Asthma, Pediatric Drugs, 2013, 15, 4, 291

    CrossRef

  25. 25
    Christina Lamers, Daniel Flesch, Manfred Schubert-Zsilavecz, Daniel Merk, Novel prostaglandin receptor modulators: a patent review (2002 – 2012) – part I: non-EP receptor modulators, Expert Opinion on Therapeutic Patents, 2013, 23, 1, 47

    CrossRef

  26. 26
    Eric S. Papierniak, David T. Lowenthal, Eloise Harman, Novel Therapies in Asthma, American Journal of Therapeutics, 2013, 20, 1, 79

    CrossRef

  27. 27
    L. Chini, E. Monteferrario, S. Graziani, V. Moschese, Novel treatments of asthma and allergic diseases, Paediatric Respiratory Reviews, 2013,

    CrossRef

  28. 28
    Merritt L. Fajt, Stacy L. Gelhaus, Bruce Freeman, Crystal E. Uvalle, John B. Trudeau, Fernando Holguin, Sally E. Wenzel, Prostaglandin D2 pathway upregulation: Relation to asthma severity, control, and TH2 inflammation, Journal of Allergy and Clinical Immunology, 2013, 131, 6, 1504

    CrossRef

  29. 29
    Lianne Beunk, Anouk Verwoerd, Frans J van Overveld, Ger T Rijkers, Role of mast cells in mucosal diseases: current concepts and strategies for treatment, Expert Review of Clinical Immunology, 2013, 9, 1, 53

    CrossRef

  30. 30
    William W. Busse, Sally E. Wenzel, Eli O. Meltzer, Edward M. Kerwin, Mark C. Liu, Nan Zhang, Yun Chon, Alison L. Budelsky, Joseph Lin, Shao-Lee Lin, Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients, Journal of Allergy and Clinical Immunology, 2013, 131, 2, 339

    CrossRef

  31. 31
    Angira Dasgupta, Helen Neighbour, Parameswaran Nair, Targeted therapy of bronchitis in obstructive airway diseases, Pharmacology & Therapeutics, 2013, 140, 3, 213

    CrossRef

  32. 32
    Patricia C. Fulkerson, Marc E. Rothenberg, Targeting eosinophils in allergy, inflammation and beyond, Nature Reviews Drug Discovery, 2013, 12, 2, 117

    CrossRef

  33. 33
    Philip M Hansbro, Grace V Scott, Ama-Tawiah Essilfie, Richard Y Kim, Malcolm R Starkey, Duc H Nguyen, Paul D Allen, Gerard E Kaiko, Ming Yang, Jay C Horvat, Paul S Foster, Th2 cytokine antagonists: potential treatments for severe asthma, Expert Opinion on Investigational Drugs, 2013, 22, 1, 49

    CrossRef

  34. 34
    Joseph R. Arron, Heleen Scheerens, John G. Matthews, Immunopharmacology, 2013,

    CrossRef

  35. 35
    Robert G. Townley, Swati Agrawal, CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils, Annals of Allergy, Asthma & Immunology, 2012, 109, 6, 365

    CrossRef

  36. 36
    Neelu Kaila, Adrian Huang, Alessandro Moretto, Bruce Follows, Kristin Janz, Michael Lowe, Jennifer Thomason, Tarek S. Mansour, Cedric Hubeau, Karen Page, Paul Morgan, Susan Fish, Xin Xu, Cara Williams, Eddine Saiah, Diazine Indole Acetic Acids as Potent, Selective, and Orally Bioavailable Antagonists of Chemoattractant Receptor Homologous Molecule Expressed on Th2 Cells (CRTH2) for the Treatment of Allergic Inflammatory Diseases, Journal of Medicinal Chemistry, 2012, 55, 11, 5088

    CrossRef

  37. 37
    Santiago Quirce, Irina Bobolea, Pilar Barranco, Emerging drugs for asthma, Expert Opinion on Emerging Drugs, 2012, 17, 2, 219

    CrossRef

  38. 38
    Peter Norman, Evaluation of WO2012078210 – development process for the preparation of a DP2 receptor antagonist; Ironwood's first development DP2 antagonist, Expert Opinion on Therapeutic Patents, 2012, 22, 10, 1257

    CrossRef

  39. 39
    Mark Ballow, Cezmi A. Akdis, Thomas B. Casale, Andrew J. Wardlaw, Sally E. Wenzel, Zuhair Ballas, Jan Lötvall, Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology, Journal of Allergy and Clinical Immunology, 2012, 130, 2, 311

    CrossRef

  40. 40
    Joanne L. Shaw, Faramarz Ashoori, Samer Fakhri, Martin J. Citardi, Amber Luong, Increased percentage of mast cells within sinonasal mucosa of chronic rhinosinusitis with nasal polyp patients independent of atopy, International Forum of Allergy & Rhinology, 2012, 2, 3
  41. 41
    Stephen T Holgate, Innate and adaptive immune responses in asthma, Nature Medicine, 2012, 18, 5, 673

    CrossRef

  42. 42
    Peter J. Barnes, Severe asthma: Advances in current management and future therapy, Journal of Allergy and Clinical Immunology, 2012, 129, 1, 48

    CrossRef

  43. 43
    P. M. O'Byrne, N. Naji, G. M. Gauvreau, Severe asthma: future treatments, Clinical & Experimental Allergy, 2012, 42, 5
  44. 44
    F. Horak, P. Zieglmayer, R. Zieglmayer, P. Lemell, L. P. Collins, M. G. Hunter, J. Steiner, T. Lewis, M. A. Payton, C. M. Perkins, R. Pettipher, The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial, Allergy, 2012, 67, 12
  45. 45
    E. Campos Alberto, E. MacLean, C. Davidson, N. S. Palikhe, J. Storie, C. Tse, D. Brenner, I. Mayers, H. Vliagoftis, A. El-Sohemy, L. Cameron, The single nucleotide polymorphism CRTh2 rs533116 is associated with allergic asthma and increased expression of CRTh2, Allergy, 2012, 67, 11
  46. 46
    Cezmi A Akdis, Therapies for allergic inflammation: refining strategies to induce tolerance, Nature Medicine, 2012, 18, 5, 736

    CrossRef

  47. 47
    Roy Pettipher, Mark Whittaker, Update on the Development of Antagonists of Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2). From Lead Optimization to Clinical Proof-of-Concept in Asthma and Allergic Rhinitis, Journal of Medicinal Chemistry, 2012, 55, 7, 2915

    CrossRef

  48. 48
    Rodolfo M. Pascual, Stephen P. Peters, Asthma, Medical Clinics of North America, 2011, 95, 6, 1115

    CrossRef